LLLT Treatment of Lung Inflammation in COVID-19

Ward Photonics

Status

Withdrawn

Conditions

Covid19

Treatments

Device: Sham Device Treatment

Device: Non-invasive red LLLT treatment to chest of patient.

Study type

Interventional

Funder types

Industry

Identifiers

NCT04524715

CP19-02

Details and patient eligibility

About

To determine if a reduction of pneumonic inflammation occurs after treatment with Low-Level Laser Therapy (LLLT) applying red-light technology in the respiratory system of COVID-19 patients suffering from acute viral pneumonia.

Full description

This clinical trial is a blinded before and after comparison of the effect on patients treated with a red-light LLLT therapy for acute lung inflammation as a result of COVID-19 infection. Patients are enrolled to undergo LLLT therapy in addition to all standard ongoing therapies for COVID-19.

Outcomes for patients receiving LLLT in addition to their standard care (the treatment group) are compared to the group receiving only standard therapy for COVID-19 (control group). Effects of LLLT treatment are measured immediately following treatment, and outcome measurements are compared to the pre-treatment baseline.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participant is diagnosed with COVID-19.
Study participant is 18 years of age or older.
Patient exhibiting moderate-to-acute respiratory distress.

Exclusion criteria

Photosensitive condition or medication.
Active chemotherapy treatment or other cancer treatment.
Autoimmune Disorder.
Pregnant, possibly pregnant or planning pregnancy prior to the end of study participation.
Developmental disability or cognitive impairment that, in the opinion of the investigator, would preclude adequate comprehension of the informed consent form and/or ability to record the necessary study measurements.